Zhang Zhao, Wang Jingyu, Dang Shaoqing, Liu Xingzi, Zhang Yuemiao, Zhang Hong
Renal Division, Peking University First Hospital, Beijing, China.
Institute of Nephrology, Peking University, Beijing, China.
Front Microbiol. 2025 Mar 4;16:1500893. doi: 10.3389/fmicb.2025.1500893. eCollection 2025.
(), a critical bacterium within the gut microbiota, plays a key role in human health and immunomodulation. Since its identification in 2004, has emerged as a significant agent in treating metabolic diseases, gastroenterological diseases, and tumor immunotherapy. Its rapid ascent in scientific translation underscores its importance in gut microbiome research. However, there has been a lack of visualization and analysis of the rapidly occurring commercialization in this field, which has critically hindered insights into the current knowledge structure and understanding of the cutting-edge of the discipline. This study employs the Web of Science Core Collection (WOSCC) and Innography platforms to provide the first comprehensive analysis of 's academic progresses and commercialization over the past two decades, highlighting its growing prominence in global health research. Our analysis delineates that, following the academic trajectory, the evolution of patents from foundational research through to application development and maturity, with particular emphasis on its expansive potential in emerging fields, including gastroenterological disorders, non-alcoholic fatty liver disease, cancer immunotherapy, stress management, and neurodegenerative disease treatment. Concluding, presents as a next-generation probiotic with vast implications for human health. Our findings provide essential insights for future research and product development, contributing to the advancement of this burgeoning field.
()是肠道微生物群中的一种关键细菌,在人类健康和免疫调节中发挥着关键作用。自2004年被发现以来,它已成为治疗代谢性疾病、胃肠疾病和肿瘤免疫疗法的重要药物。它在科学转化方面的迅速崛起凸显了其在肠道微生物组研究中的重要性。然而,该领域快速商业化过程缺乏可视化和分析,这严重阻碍了对当前知识结构的洞察以及对该学科前沿的理解。本研究利用科学网核心合集(WOSCC)和Innography平台,首次全面分析了过去二十年中()的学术进展和商业化情况,突显了其在全球健康研究中日益重要的地位。我们的分析表明,沿着学术轨迹,()的专利从基础研究发展到应用开发和成熟阶段,特别强调其在新兴领域的广阔潜力,包括胃肠疾病、非酒精性脂肪性肝病、癌症免疫疗法、压力管理和神经退行性疾病治疗。总之,()作为一种对人类健康有广泛影响的下一代益生菌脱颖而出。我们的研究结果为未来研究和产品开发提供了重要见解,有助于推动这一新兴领域的发展。
Front Microbiol. 2025-3-4
Front Med (Lausanne). 2025-2-3
Curr Pharm Biotechnol. 2024
Front Microbiol. 2022-11-10
Nutrients. 2025-1-31
Front Microbiol. 2025-4-16
Arch Microbiol. 2025-3-4
Asian J Surg. 2024-4
Int Urol Nephrol. 2024-2
Neurosci Biobehav Rev. 2023-9
Nat Microbiol. 2023-1